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Abstract
Introduction: Prospective studies investigating flavonoid intake and dementia risk are
scarce. The aims of this study were to examine associations between flavonoid intake
and the risk of incident dementia and to investigate whether this association differs in
the presence of lifestyle risk factors for dementia.
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Methods: We examined associations in 55,985 participants of the Danish Diet, Cancer,
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and Health Study followed for 23 years. The Phenol-Explorer database was used to
was obtained using Danish patient and prescription registries. Hazard ratios (HRs)
were calculated using restricted cubic splines in multivariable-adjusted Cox proportional hazards models.
Results: For incident dementia, moderate compared to low intakes of flavonols (HR:
0.90 [0.82, 0.99]), flavanol oligo+polymers (HR: 0.87 [0.79, 0.96]), anthocyanins (HR:
0.84 [0.76, 0.93]), flavanones (HR: 0.89 [0.80, 0.99]), and flavones (HR: 0.85 [0.77,
0.95]) were associated with a lower risk. For vascular dementia, moderate intakes of
flavonols (HR: 0.69 [0.53, 0.89]) and flavanol oligo + polymers (HR: 0.65 [0.51, 0.83])
were associated with lower risk. Flavonoid intakes were not significantly associated
with Alzheimer’s disease or unspecified dementia. The inverse association between
total flavonoid intake and incident dementia was stronger in “ever” smokers than in
“never” smokers and in those without hypercholesterolemia versus those with hypercholesteremia. Furthermore, the inverse association of vascular dementia with a moderate total flavonoid intake was stronger in “ever” smokers and those who were “normal”
to “overweight” versus “never” smokers or those who were “obese,” respectively.
Conclusion: A moderate intake of flavonoid-rich foods may help to reduce dementia
risk.
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medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
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1

INTRODUCTION

the association between flavonoid intake and CVD may be modified by
risk factors for CVD including smoking and alcohol intake;7,19 whether

The number of dementia cases (>50 million worldwide) is predicted

the same holds true for flavonoids and dementia warrants further

to reach 152 million by 2050.1 With coordinated action to address

investigation.

known risk factors, the 2020 Lancet Commission on Dementia estimated that up to 40% of these cases could be

prevented.2

Thus, the primary aims of this study were to investigate associations

Prevention

between incident dementia and intakes of (1) total flavonoids, (2)

is now recognized as an important strategy particularly given the lim-

flavonoid subclasses, and (3) flavonoid compounds (where significant

ited efficacy of pharmacological treatment approaches. The first line of

associations were observed for a particular subclass), in the Danish

defense proposed against the development and progression of demen-

Diet, Cancer, and Health cohort. Secondary aims were to investigate

tia is lifestyle-related factors. Dietary components, particularly those

whether these associations differed according to the presence of

that influence vascular risk factors, could be important.3

known risk factors for both CVD and dementia, that is, diabetes,

Cardiovascular risk factors such as smoking, diabetes, and hyper-

hypertension, obesity, high cholesterol, alcohol, and smoking.

tension are strongly associated with a higher risk of cognitive
impairment and dementia.4 Guidelines recommend targeting midlife
cardiovascular risk factors for prevention of dementia.5,6 The signifi-

2

METHODS

cantly lower risk of cardiovascular disease (CVD) observed with higher
dietary flavonoid intake7,8 could therefore be important in dementia

2.1

Study population

prevention. Flavonoids, a class of polyphenolic compounds found
in abundance in plant-derived foods and beverages such as fruits,

From December 1993 through May 1997, 160,725 men and women

vegetables, dark chocolate, tea, and red wine, have consistently been

from the greater areas of Copenhagen and Aarhus were invited to

associated with cardiovascular health.9 There is also a growing body of

participate in the Danish Diet, Cancer, and Health Study. The study

evidence for cognitive benefits.10 Previous studies have observed that

recruited 57,053 participants between the ages of 50 and 65 years

decline11,12

who had no previous cancer diagnosis. Of these, 56,468 completed

and improved executive function in adults with mild to moderate

a food frequency questionnaire (FFQ). All Danish residents living in

Alzheimer’s disease (AD)13 (the most common form of dementia). A

Denmark since 1968 are assigned a civil registry number, a unique

protective effect of high flavonoid intake on CVD risk, its associated

and permanent 10-digit number allowing cross-linking of participants

risk factors, and cognitive function provides a strong rationale to inves-

to nationwide registers such as the Civil Registration System, the

tigate the relationship between flavonoid intake and incident demen-

Integrated Database for Labour Market Research, the Danish National

tia. No firm conclusions can be drawn from the few prospective studies

Prescription Registry, and the Danish National Patient Register

to date that have investigated flavonoid intake and dementia.14–17

(DNPR). The DNPR holds information on all patients discharged from

total flavonoid intake is associated with lower cognitive

Flavonoids are categorized into six main subclasses based on

non-psychiatric hospitals since 1977 as well as all patient contact with

their chemical structure: flavonols, flavanols, flavanones, flavones,

psychiatric inpatient, emergency department, and outpatient specialty

anthocyanins, and isoflavones.9 As structural variations between

clinics since 1995.20 This information includes one primary diagnosis

the flavonoid subclasses and respective major compounds influence

and one or more secondary diagnoses defined by the International

bioavailability and biological activity it is informative to investigate the

Classification of Diseases (ICD): the 8th revision (ICD-8) until 1993

relationships between particular flavonoid subclasses and dementia,18

and the 10th revision (ICD-10) from 1994.21 The Danish prescription

particularly for those flavonoid subclasses including flavanols, antho-

registry holds information on all filled prescriptions from Danish

cyanins, and flavanones, for which there is evidence in the literature

pharmacies since 1994. Each drug is classified by the anatomical

for a neuro-protective effect.10 Furthermore, there is evidence that

therapeutic chemical (ATC) code.22 In the present study, participants
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were excluded if they had implausible energy intakes (<2092 kJ/d
[<500 kcal/d] and >20,920 kJ/d [>5000 kcal/d]; n = 205); if they had

RESEARCH IN CONTEXT

missing covariates or were extreme outliers (n = 214); or if they at the

1. Systematic review: The beneficial effect of a higher habit-

time of recruitment had a diagnosis of dementia (n = 64). A dementia

ual flavonoid intake on cardiovascular disease risk, its risk

diagnosis consisted of a prior diagnosis of AD (ICD-8: 29009 and

factors, and cognitive function provides a strong rationale

29010, ICD-10: F00 and G30), vascular dementia (ICD-8: 29309 and

to investigate the relationship between the range of dif-

29319, ICD-10: F01), or unspecified dementia (ICD-8: 29011, 29018,

ferent flavonoids present in the habitual diet and demen-

and 29019, ICD-10: F02 and F03.9); see Figure S1 in supporting

tia. Few prospective studies have investigated flavonoid

information.

intake and dementia, with conflicting results reported.

This study was approved by the Danish Data Protection Agency (Ref

2. Interpretation: Our findings suggest that a higher habit-

no 2012-58-0004 I-Suite nr: 6357, VD-2018-117).

ual intake of specific flavonoid subclasses, particularly the
flavonols and flavanol oligo + polymers, was associated

2.2

with a lower risk of incident, particularly vascular, demen-

Exposures

tia. The associations were non-linear; moderate flavonoid
intakes, within readily achievable daily dietary intakes,

For this study the exposures of interest were intakes of total

were associated with a lower risk of dementia.

flavonoids; flavonoid subclasses; and, if relevant, the individual

3. Future directions: The current findings require repli-

flavonoid compounds within the respective subclass, only where mean

cation in other populations to confirm the association

intakes of the subclasses were >5 mg/d. Calculations of flavonoid
intake in this cohort have been described

previously.7

between intakes of different flavonoids and dementia.

Briefly, esti-

Clinical trials and mechanistic studies to investigate the

mates of the flavonoid content of all foods and beverages in the FFQ

role of specific flavonoid subclasses on long-term cogni-

were obtained from the Phenol-Explorer database.23 All 219 flavonoid

tive health are also warranted.

compounds were grouped into 10 subclasses based on their chemical
structure (flavonols, flavanol monomers, flavanol oligo + polymers, flavanones, flavones, anthocyanins, isoflavones, dihydrochalcones, dihydroflavonols, and chalcones). Data used here are those derived from
analyses by normal phase chromatography.24 Total flavonoid intake

activity, and diet were collected by self-administered questionnaires.

was calculated by summing each of the 219 flavonoid compounds.

Anthropometry, including height and weight, and blood pressure were

The content of flavonoids was expressed as aglycone equivalents in

measured and a blood sample taken for determination of serum choles-

mg/100 g food fresh weight.24

terol levels. Average annual income (defined as household income after
taxation and interest, for the value of the Danish currency in 2015)
over 5 years was used as a representation of socioeconomic status.

2.3

Study outcomes

ICD-8 and ICD-10 codes were used to determine prevalent chronic
kidney disease, ischemic heart disease, ischemic stroke, peripheral

Our primary outcome, incident dementia, was defined as a dementia-

artery disease, heart failure, atrial fibrillation, and cancers. For treat-

related health-care visit or a prescription for an anti-dementia drug.25

ment of diabetes mellitus, both self-reported data and data on filled

About two thirds of all dementia cases are diagnosed in the secondary

prescriptions for insulin and non-insulin medication were used. Pres-

care setting and are recorded in the DNPR.26 Dementia health-care

ence of hypertension was defined as at least one of (1) systolic blood

visits were defined as a hospitalization or an outpatient visit with a

pressure ≥140 mmHg, (2) self-reported hypertension, (3) self-reported

primary or secondary diagnosis code for AD (ICD-10: F00, G30), vas-

use of blood pressure-lowering medication. Hypercholesterolemia

cular dementia (ICD-10: F01), or unspecified dementia (ICD-10: F02

was defined as at least one of (1) non-fasting serum cholesterol

and F03.9) recorded in the DNPR. These diagnoses, for total demen-

≥6.2 mmol/L, (2) self-reported hypercholesterolemia, (3) self-reported

tia, have a positive predictive value (PPV) of 85.8% in the DNPR.27 To

statin use.

capture those treated in the primary sector, we included information
on claimed prescriptions for anti-dementia drugs (ATC code: N06D).
Secondary outcomes were hospitalization or outpatient visit for each

2.5

Statistical analysis

dementia subtype discretely.
Participants’ follow-up time was based on the date of study enrollment
to, whichever came first, prescription of dementia medication, the date

2.4

Covariates

of dementia health-care visit, death, emigration, or end of follow-up
(August 2017).

At study enrolment, data on age, sex, duration of education (≤7

Cox proportional hazards models with restricted cubic splines were

years, 8–10 years, ≥11 years), smoking habits, alcohol intake, daily

used to investigate relationships between flavonoid intake and the
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primary and secondary outcomes. Using restricted cubic splines, we

STATA/IC 14.2 (StataCorp LLC) and R statistics (R Core Team, 2019).29

allowed the association to be non-linear. All hazard ratios (HRs) and

Statistical significance was set at P ≤ 0.05 (two-tailed) for all tests.

95% confidence intervals (CIs) were obtained from the model with
the exposure fitted as a continuous variable; HR estimates were
reported for the median intake in each quintile with the first quin-

3

RESULTS

tile median as the reference point, representing the lowest flavonoid
intake, and were graphed over a fine grid of x values. For visual sim-

This population of 55,985 Danish citizens, with a median (interquartile

plicity, the graphs of HRs derived from the fitting of cubic splines had

range [IQR]) age of 56 (52–60) years at study entry, had a median (IQR)

x-axis values restricted to intakes within three standard deviations

follow-up of 21 (20–22) years. During a maximum of 23 years of follow-

of the mean for each exposure. Throughout, cause-specific hazards

up (1,073,280 person-years), 2955 individuals received a diagnosis of

models were used censoring individuals at death, rather than treat-

dementia, 1348 participants had a health-care visit for AD, 329 for vas-

ing death as a competing risk.28 Cox proportional hazards assump-

cular dementia, and 1338 for unspecified dementia, with some partici-

tions were tested using log-log plots of the survival function versus

pants receiving a diagnosis of two or more types of dementia.

time and assessed for parallel appearance. Potential confounders of
flavonoid intake and dementia were chosen a priori as covariates.
Three models of adjustment were used: (1a) minimally adjusted: age

3.1

Baseline characteristics

and sex; (1b) multivariable-adjusted: age, sex, body mass index [BMI],
smoking status (current/former/never), physical activity (total daily

The median (IQR) total flavonoid intake was 494 (286–804) mg/d. The

metabolic equivalent), pure alcohol intake (g/d), duration of education,

median (IQR) intakes for the flavonoid subclasses are presented in

and socioeconomic status (income); (2) multivariable-adjusted: energy

Table 1. The baseline characteristics of the study population overall and

and potential dietary confounders; covariates in model 1b plus energy,

by quintiles of total flavonoid intake are shown in Table 2. Compared

intakes (g/d) of fish, red meat, processed meat, polyunsaturated fatty

to participants in the lowest quintile of total flavonoid intake, those

acids, monounsaturated fatty acids, and saturated fatty acids.

in higher quintiles were more likely to be female, have a lower BMI,

To examine possible effect modification, additional analy-

be more physically active, have never smoked, have a higher degree of

ses were stratified by known dementia risk factors, namely:

education, and have a higher income. Those in the higher quintiles were

diabetes

BMI

also less likely to be hypertensive or hypercholesteremic, and tended

(above/below 30 kg/m2 ), hypercholesterolemia (present/absent), alco-

to have a lower prevalence of diabetes and CVD, which in themselves

hol (above/below 20 g/d), and smoking (ever/never). When stratifying

are risk factors for dementia. Furthermore, participants in the higher

by alcohol intake we excluded all participants with an alcohol intake

quintiles consumed more fish; ate less red and processed meat; and, as

of zero (n = 1293), due to potential underlying pathologies or habits

expected, ate more fruits and vegetables.

(present/absent),

hypertension

(present/absent),

such as medication use in which alcohol intake is contraindicated (for
example anxiolytics, antidepressants, and hypnotics). As there is the
potential for residual confounding, when stratifying by smoking status,
alcohol intake, and BMI, the corresponding continuous variables were

3.2
Associations between total flavonoid intake
and incident dementia and dementia subtypes

included in the model where appropriate (smoking pack-years, alcohol
intake, and BMI, respectively). To examine the robustness of the associ-

The non-linear inverse association between total flavonoid intake and

ations, we conducted a sensitivity analysis using only dementia-related

incident dementia (Figure 1) did not reach statistical significance at

health-care visits as the outcome. All analyses were undertaken using

any level of flavonoid intake (Table 3). However, after adjusting for

TA B L E 1

a

Flavonoid subclasses, natural sources, and intake per day

Flavonoid subclass

Natural sources23

Intake (mg/d)a

Flavonols

Tea (black), fruit (berries and pome), cocoa, and onions

38 [23–73]

Flavanol monomers

Tea (black and green), wine, cocoa, chocolate, fruit
(pome, drupe, tropical, and berries), nuts, and beans

66 [25–268]

Flavanol oligo+polymers

Tea (black and green), wine, cocoa, fruit (pome, drupe,
tropical, and berries), and beans

255 [157–395]

Flavones

Olive oil, olives, herbs, and whole grain wheat

5 [3–8]

Flavanones

Citrus fruit and herbs

17 [8–38]

Anthocyanins

Pomegranate, berries, and red wine

20 [11–50]

Isoflavones

Soybeans, soy foods, and beans

<1

Median [interquartile range].

5 of 16

BONDONNO ET AL .

TA B L E 2

Baseline characteristics of study population
Total population
n = 55,985

Total flavonoid intake quintiles
Q1
n = 11,197

Q2
n = 11,197

Q3
n = 11,197

Q4
n = 11,197

Q5
n = 11,197

Total flavonoid intake
(mg/d)

494 [286–804]

173 [127–212]

320 [286–356]

494 [441–548]

726 [659–804]

1201 [1024–1435]

Sex n (% male)

26,626 (47.6)

6469 (57.8)

5733 (51.2)

5329 (47.6)

4988 (44.5)

4107 (36.7)

Age (y)

56 [52–60]

56 [52–60]

56 [52–60]

56 [52–60]

56 [52–60]

55 [52–59]

BMI (kg/m )

25.5 [23.3–28.2]

26.1 [23.8–28.9]

25.9 [23.6–28.5]

25.6 [23.3–28.3]

25.3 [23.2–27.9]

24.9 [22.7–27.4]

MET score

56.5 [37.0–84.8]

51.0 [32.0–78.0]

55.5 [36.3–84.0]

57.5 [38.3–85.0]

58.3 [38.5–87.0]

60.0 [39.5–88.5]

Never

19,648 (35.1)

2716 (24.3)

3743 (33.4)

3991 (35.6)

4458 (39.8)

4740 (42.3)

Former

16,134 (28.8)

2692 (24.0)

3026 (27.0)

3264 (29.2)

3594 (32.1)

3558 (31.8)

Current

20,203 (36.1)

5789 (51.7)

4428 (39.5)

3942 (35.2)

3145 (28.1)

2899 (25.9)

≤7 y

18,438 (32.9)

5120 (45.7)

4263 (38.1)

3603 (32.2)

3024 (27.0)

2428 (21.7)

8–10 y

25,789 (46.1)

4887 (43.6)

5257 (47.0)

5335 (47.6)

5315 (47.5)

4995 (44.6)

≥11 y

11,730 (21.0)

1184 (10.6)

1673 (14.9)

2255 (20.1)

2851 (25.5)

3767 (33.6)

2

Smoking status, n (%)

Education, n (%)

Mean household income, n (%)
≤3,94,700 DKK/y

13,886 (24.8)

3342 (29.8)

2744 (24.5)

2709 (24.2)

2574 (23.0)

2517 (22.5)

3,94,701–5,70,930
DKK/y

14,000 (25.0)

3268 (29.2)

2998 (26.8)

2714 (24.2)

2601 (23.2)

2419 (21.6)

5,70,931–7,58,297
DKK/y

14,049 (25.1)

2915 (26.0)

3032 (27.1)

2900 (25.9)

2620 (23.4)

2582 (23.1)

>7,58,297 DKK/y

14,050 (25.1)

1672 (14.9)

2423 (21.6)

2874 (25.7)

3402 (30.4)

3679 (32.9)

Hypertensive

24,913 (44.5)

5355 (47.8)

5098 (45.5)

5047 (45.1)

4838 (43.2)

4575 (40.9)

Hypercholesterolemic

28,590 (51.1)

6052 (54.1)

5784 (51.7)

5830 (52.1)

5617 (50.2)

5307 (47.4)

Diabetes

1177 (2.1)

279 (2.5)

219 (2.0)

253 (2.3)

215 (1.9)

211 (1.9)

Heart failure

220 (0.4)

56 (0.5)

54 (0.5)

39 (0.3)

40 (0.4)

31 (0.3)

Ischemic stroke

778 (1.4)

218 (1.9)

151 (1.3)

145 (1.3)

130 (1.2)

134 (1.2)

Ischemic heart
disease

2192 (3.9)

586 (5.2)

422 (3.8)

435 (3.9)

396 (3.5)

353 (3.2)

Peripheral artery
disease

498 (0.9)

171 (1.5)

114 (1.0)

84 (0.8)

61 (0.5)

68 (0.6)

Atrial fibrillation

277 (0.5)

57 (0.5)

55 (0.5)

59 (0.5)

49 (0.4)

57 (0.5)

Comorbidities, n (%)

CKD

202 (0.4)

43 (0.4)

33 (0.3)

44 (0.4)

41 (0.4)

41 (0.4)

Cancer

246 (0.4)

55 (0.5)

42 (0.4)

60 (0.5)

33 (0.3)

56 (0.5)

Medication use, n (%)
Insulin treated

380 (0.7)

78 (0.7)

65 (0.6)

86 (0.8)

80 (0.7)

71 (0.6)

Antihypertensive

6893 (12.3)

1360 (12.1)

1421 (12.7)

1405 (12.5)

1360 (12.1)

1347 (12.0)

Statin

1073 (1.9)

262 (2.3)

210 (1.9)

221 (2.0)

212 (1.9)

168 (1.5)

Never

15,965 (28.5)

2605 (23.3)

3047 (27.2)

3268 (29.2)

3268 (29.2)

3777 (33.7)

Current

8816 (15.7)

1293 (11.5)

1569 (14.0)

1698 (15.2)

2001 (17.9)

2255 (20.1)

Former

4547 (8.1)

821 (7.3)

844 (7.5)

895 (8.0)

934 (8.3)

1053 (9.4)

HRT

(Continues)
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(Continued)
Total population
n = 55,985

Total flavonoid intake quintiles
Q1
n = 11,197

Q2
n = 11,197

Q3
n = 11,197

Q4
n = 11,197

Q5
n = 11,197

NSAID

18,138 (32.6)

3538 (31.8)

3528 (31.7)

3636 (32.7)

3636 (32.6)

3800 (34.2)

Aspirin

7086 (12.7)

1391 (12.4)

1366 (12.2)

1434 (12.8)

1392 (12.4)

1503 (13.4)

Energy (kj/d)

9500
[7857–11,369]

8609 [7027–
10,387]

9262
[7718–11,000]

9752
[8140–11,587]

9936
[8320–11,830]

9929
[8258–11,891]

Total fish intake
(g/d)

38 [25–55]

33 [22–49]

38 [25–54]

34 [27–57]

41 [28–59]

40 [27–57]

Red meat intake
(g/d)

78 [57–107]

80 [58–108]

81 [59–110]

80 [58–110]

78 [57–107]

72 [52–99]

Processed meat
intake (g/d)

25 [14–40]

28 [17–45]

26 [16–42]

25 [14–40]

23 [14–38]

20 [11–34]

Dietary fiber intake
(g/d)

20 [16–25]

16 [13–20]

19 [16–23]

21 [17–25]

22 [18–27]

23 [19–29]

Saturated FA (g/d)

31 [24–39]

29 [23–37]

31 [24–39]

32 [24–40]

32 [25–41]

32 [24–41]

Polyunsaturated FA
(g/d)

13 [10–17]

12 [9–16]

13 [10–17]

14 [10–18]

14 [11–18]

14 [10–18]

Monounsaturated
FA (g/d)

27 [21–35]

26 [20–34]

27 [21–35]

28 [22–35]

28 [22–35]

27 [21–34]

Fruit intake (g/d)

171 [95–281]

87 [44–140]

162 [97–237]

193 [114–300]

224 [139–360]

240 [141–390]

Vegetable intake
(g/d)

161 [105–231]

114 [71–170]

150 [99–211]

168 [114–235]

184 [127–253]

196 [135–272]

Alcohol intake (g/d)

13 [6–31]

11 [3–24]

13 [6–25]

15 [6–34]

14 [7–32]

13 [6–32]

Dietary characteristics

Note: Data expressed as median [IQR] unless otherwise stated.
Abbreviations: BMI, body mass index; CKD, chronic kidney disease; DKK, Danish Krone; FA, fatty acids; HRT, hormone replacement therapy; IQR, interquartile range; MET, metabolic equivalent; NSAID, nonsteroidal anti-inflammatory drug.

demographic and lifestyle factors (Model 1b), participants in quintiles (Q) 2 and 3 had a 24% (HR [95% CI]: 0.76 [0.62, 0.93]) and 30%

3.4
Associations between major flavonoid
compound intakes and incident dementia

(0.70 [0.54, 0.91]) lower risk of vascular dementia, respectively, compared to participants in Q1 (Table 4). Although total flavonoid intake

Associations between intakes of flavonoid compounds and incident

appeared to be non-linearly inversely associated with AD, this did not

dementia were assessed only for the subclasses significantly asso-

reach statistical significance at any level of flavonoid intake (Figure 1).

ciated with a lower risk of dementia in at least one intake quintile

Total flavonoid intake did not appear to be associated with unspecified

(flavonols, flavanol oligo + polymers, anthocyanins, flavanones, and

dementia (Figure 1).

flavones). Intakes of quercetin, procyanidin trimers, hesperidin, apigenin, delphinidin, and malvidin were associated with incident dementia (Figure S1). For all aforementioned compounds, the lowest risks

3.3
Associations between flavonoid subclass
intakes and incident dementia

were seen for moderate intakes (participants in Q3 and Q4; Table S1
in supporting information).

Associations between intakes of flavonols, flavanol oligo + polymers, anthocyanins, flavanones, and flavones and incident dementia were non-linear (Table 3 and Figure 2). For the aforementioned
subclasses, the lowest risks seen for moderate intakes (Q3 and

3.5
Associations between total flavonoid intakes
and incident dementia stratified by risk factors for
dementia

Q4). No evidence of an association between the flavanol monomers
and incident dementia was observed. Similar associations were also

The association between total flavonoid intake and incident dementia,

observed after further adjustments for potential dietary confounders

stratified by risk factors for dementia, is presented in Figure 3. The

(Model 2).

association appeared to differ by smoking and hypercholesterolemia
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Q3. No evidence of an association between the anthocyanin, flavanol
monomer, flavanone, or flavone subclasses and incident dementia was
observed.

3.7
Associations between total flavonoid intakes
and vascular dementia stratified by risk factors for
dementia
The association between total flavonoid intake and vascular dementia, stratified by risk factors for dementia, is presented in Figure 5.
The association appeared to differ by smoking status, alcohol intake,
BMI, and hypocholesteremia; there was a statistically significant lower
risk of vascular dementia with a moderate total flavonoid intake for
“ever” smokers (Q3 vs. Q1 HR [95% CI]: 0.70 [0.53, 0.91]) and those
who were “normal” to “overweight” (Q3 vs. Q1: 0.64 [0.48, 0.85], but
not for “never” smokers [Q3 vs. Q1: 0.95 [0.48, 1.89]) or those who
were “obese” (Q3 vs. Q1: 1.14 [0.60, 2.18]), after multivariable adjustments (Model 1b). Furthermore, the association appeared to be “Ushaped” in high alcohol consumers and participants who were not
hypercholesteremic. We did not stratify by baseline diabetes status
as there were very few cases of vascular dementia in this subgroup
(n = 18).

3.8
F I G U R E 1 Cubic spline curves depicting the association between
total flavonoid intake and both total dementia incidence (n = 2955)
and the incidence of dementia subtypes; Alzheimer’s disease
(n = 1348), vascular dementia (n = 329), and unspecified dementia
(n = 1338). Hazard ratios are based on Cox proportional hazards
models adjusted for age, sex, body mass index, smoking status,
physical activity, alcohol intake, education, and socioeconomic status
(income), and are comparing the specific level of flavonoid intake
(horizontal axis) to the median intake for participants in the lowest
intake quintile (173 mg/d).

Sensitivity analysis

Defining incident dementia using only dementia-related health-care
visits (n = 2413) the observed association with total flavonoid intakes
was stronger (Figure S3 in supporting information); compared to those
in Q1, the risk of incident dementia was statistically significantly
lower for participants in Q2–4 (HR [95% CIs] for Q2: 0.91 [0.84,
0.99]; Q3: 0.86 [0.77, 0.96]; Q4: 0.86 [0.77, 0.96]; Q5: 0.89 [0.79,
1.01])

4

DISCUSSION

status in that there was a statistically significant lower risk of incident dementia at a moderate total flavonoid intake for “ever” smokers

Primary prevention of dementia through modification of lifestyle-

(Q3 vs. Q1 HR [95% CI]: 0.89 [0.80, 0.99]) and those without hyperc-

related factors, such as diet, is now recognized to be of importance.3

holesterolemia (Q4 vs. Q1 HR [95% CI]: 0.84 [0.72, 0.96]), but not for

There is the potential to lower the risk of developing dementia with

“never” smokers (Q3 vs. Q1: 1.07 [0.87, 1.31], or those with hyperc-

evidence-based dietary guidelines focusing on specific dietary compo-

holesterolemia (Q4 vs. Q1 HR [95% CI]: 1.00 [0.87, 1.14]), after mul-

nents, especially in high-risk populations. In this prospective cohort

tivariable adjustments (Model 1b).

study of 55,985 Danish men and women, moderate intakes of flavonols,
flavanol oligo + polymers, anthocyanins, flavanones, and flavones were
associated with a lower risk of incident dementia. Additionally, we

3.6
Associations between flavonoid subclass
intakes and vascular dementia

observed that moderate intakes of flavonols and flavanol oligo + polymers were significantly associated with a 24% to 30% lower risk of
vascular dementia. The association between total flavonoid intake and

Associations between flavonoid subclasses and vascular dementia

incident dementia appeared to differ by smoking and hypercholes-

appeared to be non-linear (Table 4 and Figure 4). Intakes of the flavonol

terolemia status while the association between total flavonoid intake

and flavanol oligo + polymer subclasses were associated with incident

and vascular dementia appeared to differ by smoking status, alcohol

vascular dementia, with the lowest risks observed for participants in

intake, BMI, and hypocholesteremia.
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Hazard ratios of incident dementia by quintiles of flavonoid intake
Flavonoid intake quintiles
Q1 (n = 11,197)

Q2 (n = 11,197)

Q3 (n = 11,197)

Q4 (n = 11,197)

Q5 (n = 11,197)

No. events

602

595

604

577

577

Intake (mg/d)a

173 (6–251)

320 (251–394)

495 (394–601)

726 (601–908)

1201 (908–3552)

Model 1a

ref.

0.94 (0.87, 1.01)

0.88 (0.8, 0.97)

0.85 (0.77, 0.93)

0.87 (0.79, 0.96)

Model 1b

ref.

0.96 (0.89, 1.04)

0.93 (0.84, 1.02)

0.91 (0.82, 1.00)

0.95 (0.85, 1.05)

Model 2

ref.

0.95 (0.88, 1.02)

0.91 (0.82, 1.01)

0.89 (0.80, 0.98)

0.93 (0.83, 1.04)

Total flavonoids

HR (95% CI)

Flavonols
No. events

639

597

559

606

554

Intake (mg/d)a

15 (0–20)

26 (20–32)

38 (32–50)

66 (50–82)

116 (83–251)

HR (95% CI)
Model 1a

ref.

0.91 (0.85, 0.97)

0.86 (0.79, 0.94)

0.85 (0.78, 0.94)

0.86 (0.78, 0.95)

Model 1b

ref.

0.93 (0.88, 1.00)

0.90 (0.82, 0.99)

0.92 (0.83, 1.01)

0.94 (0.85, 1.04)

Model 2

ref.

0.91 (0.85, 0.98)

0.87 (0.79, 0.96)

0.89 (0.80, 0.98)

0.92 (0.82, 1.02)

613

572

594

623

553

14 (0–21)

30 (21–45)

66 (45–115)

260 (115–281)

473 (281–916)

Model 1a

ref.

0.97 (0.93, 1.01)

0.92 (0.83, 1.02)

0.89 (0.81, 0.98)

0.89 (0.81, 0.98)

Model 1b

ref.

0.98 (0.94, 1.03)

0.96 (0.87, 1.06)

0.96 (0.87, 1.06)

0.97 (0.88, 1.07)

Model 2

ref.

0.98 (0.94, 1.02)

0.95 (0.85, 1.05)

0.96 (0.87, 1.06)

0.97 (0.88, 1.08)

595

644

556

594

566

91 (0–136)

178 (136–217)

255 (217–302)

359 (302–434)

536 (434–2254)

Model 1a

ref.

0.92 (0.85, 1.00)

0.86 (0.79, 0.94)

0.81 (0.74, 0.89)

0.83 (0.75, 0.91)

Model 1b

ref.

0.95 (0.88, 1.03)

0.91 (0.83, 1.00)

0.87 (0.79, 0.96)

0.89 (0.80, 0.99)

Model 2

ref.

0.94 (0.87, 1.02)

0.89 (0.81, 0.98)

0.85 (0.76, 0.94)

0.87 (0.77, 0.97)

Flavanol monomers
No. events
Intake (mg/d)

a

HR (95% CI)

Flavanol oligo + polymers
No. events
Intake (mg/d)

a

HR (95% CI)

Anthocyanins
No. events

640

589

504

577

645

Intake (mg/d)a

5 (0–10)

13 (10–17)

20 (17–24)

36 (24–53)

71 (53–397)

HR (95% CI)
Model 1a

ref.

0.83 (0.77, 0.90)

0.79 (0.72, 0.88)

0.86 (0.78, 0.95)

0.99 (0.9, 1.10)

Model 1b

ref.

0.87 (0.80, 0.94)

0.84 (0.76, 0.93)

0.91 (0.82, 1.00)

1.03 (0.92, 1.15)

Model 2

ref.

0.86 (0.79, 0.93)

0.83 (0.75, 0.92)

0.90 (0.81, 0.99)

1.01 (0.90, 1.13)

658

541

551

573

632

3 (0–6)

9 (6–13)

17 (13–26)

32 (26–49)

70 (49–564)

Flavanones
No. events
Intake (mg/d)

a

HR (95% CI)
Model 1a

ref.

0.91 (0.85, 0.97)

0.86 (0.77, 0.95)

0.89 (0.81, 0.98)

0.98 (0.89, 1.08)

Model 1b

ref.

0.93 (0.87, 0.99)

0.89 (0.80, 0.99)

0.93 (0.84, 1.02)

1.01 (0.92, 1.12)

Model 2

ref.

0.92 (0.86, 0.98)

0.87 (0.78, 0.98)

0.91 (0.83, 1.01)

0.99 (0.89, 1.10)

(Continues)
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(Continued)
Flavonoid intake quintiles
Q1 (n = 11,197)

Q2 (n = 11,197)

Q3 (n = 11,197)

Q4 (n = 11,197)

Q5 (n = 11,197)

No. events

619

552

559

587

638

Intake (mg/d)a

2 (0–3)

4 (3–4)

5 (4–6)

7 (6–9)

11 (9–51)

Model 1a

ref.

0.84 (0.77, 0.92)

0.82 (0.74, 0.90)

0.84 (0.76, 0.92)

0.91 (0.82, 1.00)

Model 1b

ref.

0.87 (0.79, 0.95)

0.85 (0.77, 0.95)

0.88 (0.80, 0.97)

0.95 (0.86, 1.05)

Model 2

ref.

0.86 (0.78, 0.94)

0.84 (0.75, 0.93)

0.86 (0.78, 0.95)

0.92 (0.82, 1.03)

Flavones

HR (95% CI)

Notes: Hazard ratios (95% CI) for incident dementia during 23 years of follow-up, obtained from restricted cubic splines based on Cox proportional hazards
models. Model 1a adjusted for age and sex; Model 1b adjusted for age, sex, BMI, smoking status, physical activity, alcohol intake, education, and socioeconomic status (income); Model 2 adjusted for all covariates in model 1b plus energy, intakes of fish, red meat, processed food, polyunsaturated fatty acids,
monounsaturated fatty acids, and saturated fatty acids.
a
Median; range in parentheses (all such values).
Abbreviations: BMI, body mass index; CI, confidence interval; HR, hazard ratio.

TA B L E 4

Hazard ratios of vascular dementia by quintiles of flavonoid intake
Flavonoid intake quintiles
Q1 (n = 11,197)

Q2 (n = 11,197)

Q3 (n = 11,197)

Q4 (n = 11,197)

Q5 (n = 11,197)

85

63

61

57

63

173 (6–251)

320 (251–394)

495 (394–601)

726 (601–908)

1201 (908–3552)

Model 1a

ref.

0.70 (0.57, 0.86)

0.61 (0.47, 0.78)

0.66 (0.51, 0.86)

0.74 (0.55, 0.98)

Model 1b

ref.

0.76 (0.62, 0.93)

0.70 (0.54, 0.91)

0.78 (0.59, 1.03)

0.88 (0.65, 1.19)

Model 2

ref.

0.75 (0.61, 0.92)

0.68 (0.52, 0.89)

0.76 (0.56, 1.01)

0.85 (0.62, 1.18)

Total flavonoids
No. events
Intake (mg/d)

a

HR (95% CI)

Flavonols
No. events

88

72

49

54

66

Intake (mg/d)a

15 (0–20)

26 (20–32)

38 (32–50)

66 (50–82)

116 (83–251)

Model 1a

ref.

0.71 (0.59, 0.85)

0.60 (0.47, 0.78)

0.70 (0.54, 0.91)

0.75 (0.56, 1.00)

Model 1b

ref.

0.76 (0.64, 0.92)

0.69 (0.53, 0.89)

0.83 (0.63, 1.10)

0.91 (0.67, 1.23)

Model 2

ref.

0.73 (0.60, 0.88)

0.64 (0.48, 0.84)

0.79 (0.59, 1.05)

0.86 (0.63, 1.19)

HR (95% CI)

Flavanol monomers
No. events

81

67

64

56

61

Intake (mg/d)a

14 (0–21)

30 (21–45)

66 (45–115)

260 (115–281)

473 (281–916)

Model 1a

ref.

0.84 (0.74, 0.96)

0.67 (0.50, 0.90)

0.75 (0.57, 0.99)

0.78 (0.58, 1.03)

Model 1b

ref.

0.88 (0.77, 1.00)

0.75 (0.55, 1.01)

0.89 (0.67, 1.20)

0.93 (0.69, 1.26)

Model 2

ref.

0.87 (0.77, 1.00)

0.73 (0.54, 1.00)

0.90 (0.66, 1.21)

0.94 (0.69, 1.27)

90

64

53

62

60

91 (0–136)

178 (136–217)

255 (217–302)

359 (302–434)

536 (434–2254)

Model 1a

ref.

0.63 (0.51, 0.78)

0.57 (0.45, 0.72)

0.63 (0.49, 0.82)

0.69 (0.52, 0.91)

Model 1b

ref.

0.70 (0.57, 0.86)

0.65 (0.51, 0.83)

0.74 (0.56, 0.97)

0.81 (0.60, 1.09)

Model 2

ref.

0.68 (0.55, 0.85)

0.63 (0.49, 0.82)

0.71 (0.53, 0.94)

0.77 (0.56, 1.06)

HR (95% CI)

Flavanol oligo+polymers
No. events
Intake (mg/d)

a

HR (95% CI)

(Continues)
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(Continued)
Flavonoid intake quintiles
Q1 (n = 11,197)

Q2 (n = 11,197)

Q3 (n = 11,197)

Q4 (n = 11,197)

Q5 (n = 11,197)

Anthocyanins
No. events

71

69

49

62

78

Intake (mg/d)a

5 (0–10)

13 (10–17)

20 (17–24)

36 (24–53)

71 (53–397)

Model 1a

ref.

0.80 (0.63, 1.02)

0.74 (0.55, 1.01)

0.79 (0.60, 1.04)

0.98 (0.72, 1.32)

Model 1b

ref.

0.90 (0.71, 1.15)

0.88 (0.65, 1.19)

0.91 (0.68, 1.22)

1.08 (0.79, 1.50)

Model 2

ref.

0.90 (0.71, 1.15)

0.88 (0.64, 1.19)

0.92 (0.68, 1.23)

1.08 (0.78, 1.50)

85

51

67

62

64

3 (0–6)

9 (6–13)

17 (13–26)

32 (26–49)

70 (49–564)

Model 1a

ref.

0.86 (0.70, 1.05)

0.78 (0.57, 1.06)

0.81 (0.61, 1.07)

0.88 (0.66, 1.18)

Model 1b

ref.

0.91 (0.75, 1.11)

0.87 (0.63, 1.19)

0.91 (0.69, 1.21)

0.97 (0.73, 1.31)

Model 2

ref.

0.91 (0.74, 1.11)

0.86 (0.62, 1.18)

0.90 (0.68, 1.20)

0.96 (0.71, 1.29)

68

61

65

61

74

2 (0–3)

4 (3–4)

5 (4–6)

7 (6–9)

11 (9–51)

Model 1a

ref.

0.87 (0.66, 1.14)

0.84 (0.62, 1.14)

0.84 (0.63, 1.12)

0.92 (0.68, 1.25)

Model 1b

ref.

0.97 (0.73, 1.27)

0.96 (0.71, 1.30)

0.98 (0.73, 1.30)

1.05 (0.78, 1.44)

Model 2

ref.

0.98 (0.74, 1.29)

0.98 (0.74, 1.29)

1.00 (0.74, 1.36)

1.09 (0.77, 1.52)

HR (95% CI)

Flavanones
No. events
Intake (mg/d)

a

HR (95% CI)

Flavones
No. events
Intake (mg/d)

a

HR (95% CI)

Notes: Hazard ratios (95% CI) for vascular dementia during 23 years of follow-up, obtained from restricted cubic splines based on Cox proportional hazards
models. Model 1a adjusted for age and sex; Model 1b adjusted for age, sex, BMI, smoking status, physical activity, alcohol intake, education, and socioeconomic status (income); Model 2 adjusted for all covariates in model 1b plus energy, intakes of fish, red meat, processed food, polyunsaturated fatty acids,
monounsaturated fatty acids, and saturated fatty acids.
a
Median; range in parentheses (all such values).
Abbreviations: BMI, body mass index; CI, confidence interval; HR, hazard ratio.

While there is a growing body of evidence that particular dietary

for 19.7 years, 193 incident cases of dementia), individuals with the

patterns, such as the Mediterranean diet, are associated with a lower

highest flavonol, anthocyanins, and flavonoid polymers intake (based

risk of dementia30 and reduced dementia-related neuropathology,31

on a cumulative average across five exams) had a 46%, 76%, and 42%

to our knowledge few prospective studies to date have investigated

lower risk of dementia, respectively, compared to participants with the

flavonoid intake and dementia. In the Paquid study, flavonoid intake

lowest intakes.32 Evidence from observational studies investigating

(mean, 14.4 mg/d) was associated with a 51% (relative risk: 0.49, 95%

flavonoid-rich foods and risk of dementia indicate potential protective

CI: 0.26, 0.92) lower risk of dementia (66 incident cases) in 1367 sub-

effects for vegetables, particularly green leafy vegetables; fruit, partic-

jects over the age of 65 and followed up for 5 years.14 Lefèvre-Arbogast

ularly berries; and coffee and tea.33 The present study is the largest

et al. identified a pattern of polyphenol intake (mean, 1071 mg/d)

study to date investigating flavonoid intake and risk of dementia (2955

associated with a 50% (HR: 0.50, 95% CI: 0.32, 0.80) lower risk of

incident cases diagnosed during follow-up). It is, however, difficult to

dementia (256 incident cases) in 1329 older adults followed for 12

compare results between our study and previous studies due to incon-

years in the Three-City Study.17 Conversely, flavonoid intake at base-

sistencies in the number of different flavonoid subclasses considered

line (mean, 28.5 mg/d) was not associated with dementia (465 incident

and methods of calculation. For reference, median and mean flavonoid

cases) in 5395 participants of the Rotterdam Study after a mean of 9.6

intakes in the present study were 494 and 596 mg/d, respectively, cal-

years

follow-up.15

Flavonoid intake (estimated using a mean intake of

culated using estimates of 219 compounds. Our results are consis-

tea as a proxy, 2 to 6 mg/d), was not associated with dementia (235

tent with recent flavonoid intake calculations using the United States

incident cases) after 30 years of follow-up in 2459 men and women

Department of Agriculture and Phenol-Explorer databases.24,34,35

enrolled in the Honolulu-Asia Aging Study.16 More recently, partici-

Of dementia subtypes, a statistically significant association was

pants of the Framingham Heart Study offspring cohort (2801 followed

only observed between total flavonoid intake and vascular dementia.
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F I G U R E 2 Hazard ratios based on cubic spline curves to depict the association between flavonoid subclass intakes (mg/d) and all cases of
incident dementia among participants of the Danish Diet, Cancer, and Health cohort. Hazard ratios are based on Cox proportional hazards models
adjusted for age, sex, body mass index, smoking status, physical activity, alcohol intake, education, and socioeconomic status (income), and are
comparing the specific level of flavonoid intake (horizontal axis) to the median intake for participants in the lowest intake quintile

Compared to those with low flavonoid intakes, a 24% to 30% lower

flavonoids on cardiovascular health and by extension, cerebrovascular

risk of vascular dementia was observed for participants with moderate

health.9,39 While a wide range of potential biological mechanisms have

flavonoid intakes. Vascular dementia can be a consequence of stroke

been reported for flavonoids and flavonoid-rich foods,40 benefits of

and microvascular disease, and is estimated to account for 15% to

specific flavonoid subclasses on vascular health could be mediated by

20% of all dementia cases.36 It is important to note, however, that AD

enhanced nitric oxide bioavailability,9 increased expression of heme-

(the most common form of dementia) and vascular dementia are not

oxygenase-1,41 inhibition of angiotensin-converting enzyme activity,42

distinct, and there is an overlap in underlying pathology; cerebrovas-

effects on cholesterol,43 and improved inflammatory status,44 or a

cular dysfunction is prominent in

AD37

and pure vascular dementia

complex milieu of all these beneficial effects.

(dementia caused solely by vascular pathology) is relatively rare.38

Interestingly, while no association was observed between total

There is a growing body of evidence supporting the beneficial effects of

flavonoid intake and incident dementia, a non-linear inverse
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F I G U R E 3 Multivariable-adjusted association between total flavonoid intake and incident dementia stratified by baseline smoking status,
alcohol intake, body mass index (BMI), sex, diabetes status, cholesterol levels, and hypertension status. Hazard ratios are based on Cox
proportional hazards models and are comparing the specific level of flavonoid intake (horizontal axis) to the median intake for participants in the
lowest intake quintile (173 mg/d). All analyses were standardized for age, sex, BMI, smoking, physical activity, alcohol intake, education, and
socioeconomic status (income)

association was observed for specific flavonoid subclasses and

and flavanones are the most neuro-protective of all the flavonoids

some of their individual flavonoid compounds. This is not surprising

subclasses, improving measures of cognitive function and limiting cog-

given the structural variations between the flavonoid subclasses, and

nitive decline.45–53 A moderate intake of these flavonoid subclasses is

their respective major compounds, which influences bioavailability

well within achievable daily dietary limits: one cup of tea, one apple,

and biological activity.18 Evidence for a threshold after which higher

one orange, 50 g of blueberries, and 50 g of dark chocolate would

flavonoid intakes afford no added benefit, is not new and has been seen

provide these flavonoid subclasses and more than 500 mg of total

for other outcomes in the same cohort.7,19 Furthermore, our study

flavonoids.

suggests a U-shaped association between intakes of several flavonoid

The association between total flavonoid intake and both inci-

subclasses and incident dementia. We hypothesize that this is driven

dent and vascular dementia was only present in current and for-

by the co-occurrence of other, potentially detrimental, dietary factors

mer smokers; there was no association in participants who had

(e.g., added sugar in anthocyanin-rich fruit juice/squash) in flavonoid-

never smoked. Smoking is strongly associated with a higher risk of

rich foods. A lower risk of dementia was observed at moderate intakes

dementia.54 A recent meta-analysis of 37 studies observed a 30%

of the flavonols, flavanol oligo + polymers, anthocyanins, flavanones.

higher risk of all-cause dementia (relative risk: 1.30, 95% CI: 0.18,

and flavones subclasses. These findings support a growing body of

0.45) for participants who currently smoke compared to those who

evidence in the literature that flavonols, flavanols, anthocyanins,

have never smoked.54 It is proposed that smoking increases the risk of
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F I G U R E 4 Hazard ratios based on cubic spline curves to depict the association between flavonoid subclass intakes (mg/d) and all cases of
vascular dementia among participants of the Danish Diet, Cancer, and Health cohort. Hazard ratios are based on Cox proportional hazards models
adjusted for age, sex, body mass index, smoking status, physical activity, alcohol intake, education, and socioeconomic status (income), and are
comparing the specific level of flavonoid intake (horizontal axis) to the median intake for participants in the lowest intake quintile

vascular dementia via detrimental effects on cerebrovascular health.55

cial role in flavonoid metabolism.58 However, as the number of partic-

In the current study, the inverse association of total flavonoid intake

ipants who were “obese” was low and associated confidence intervals

with incident dementia observed in participants who smoked or had

are wide, this requires further investigation. Furthermore, the pres-

ever smoked is likely related to the protective effect of flavonoids on

ence of an association between total flavonoid intake and vascular

vascular health. Of note, a randomized controlled trial conducted in

dementia, but not incident dementia, in participants who were hyperc-

healthy individuals who smoked observed that flavonoid-rich grape

holesteremic at baseline requires further investigation taking into con-

juice intake restored vascular function.56 That the association between

sideration treatment or changes in hypercholesteremia status during

total flavonoid intake and vascular dementia was only present in partic-

follow-up. Given the low number of vascular dementia cases in this

ipants who were “normal” to “overweight” at baseline could be related

cohort, and that associations were stratified over several effect mod-

to differences in gut microbiome

composition,57

which plays a cru-

ifiers thereby increasing the likelihood of spurious associations, these
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F I G U R E 5 Multivariable-adjusted association between total flavonoid intake and vascular dementia stratified by baseline smoking status,
alcohol intake, body mass index (BMI), sex, diabetes status, hypertension status, and cholesterol levels. Hazard ratios are based on Cox
proportional hazards models and are comparing the specific level of flavonoid intake (horizontal axis) to the median intake for participants in the
lowest intake quintile (173 mg/d). All analyses were standardized for age, sex, BMI, smoking, physical activity, alcohol intake, education, and
socioeconomic status (income)

stratified analyses should be interpreted with caution and viewed as

subclasses, a number of statistical tests were performed. However,

exploratory.

these tests were hypothesis driven given the current knowledge on the

Our cohort study has a number of strengths. The 23-year duration of

bioavailability, bioefficacy, and mechanistic understanding of the dif-

follow-up with very limited loss to follow-up allowed for the accumula-

ferent subclasses. Additionally, other than a dementia diagnosis (study

tion of a large number of incident cases despite the protracted nature

exclusion criteria), there was no information on cognitive impairment

of the disease. The length of follow-up and age of enrolment (∼50

at baseline, nor detailed information at follow-up (beyond a diagnosis

years) also allowed for the examination of flavonoid intake in associa-

of dementia in the DNPR or prescription for an anti-dementia drug in

tion with mid-life risk factors. This is important as substantial evidence

the DNPR). Additionally, dementia incidence may have been underesti-

indicates that mid-life risk factors (hypertension, obesity, cholesterol,

mated as participants who did not take medication for the treatment of

smoking, and physical activity) are important for predicting dementia

dementia and who did not have a health-care visit with a dementia diag-

risk in later life.4

nosis code would have been missed. Further, no studies are available

As this is an observational study a number of limitations apply. We

providing PPVs for dementia diagnoses defined as either a dementia-

are unable to infer causality or rule out residual or unmeasured con-

related health-care visit or a prescription for an anti-dementia drug.

founding factors. Flavonoids could also be a surrogate marker of a

However, the association between total flavonoid intake and incident

healthier diet and lifestyle. However, the association between a higher

dementia was stronger in a sensitivity analysis using only dementia-

flavonoid intake and a lower risk of vascular dementia was still present

related health-care visits as the outcome, which has a PPV of 85.8%

after adjustment for lifestyle factors and other indicators of a healthy

in the DNPR.27 This may be because the inclusion of a redeemed

diet. While the 23-year duration of follow-up allowed for the long pre-

prescription for an anti-dementia drug in the outcome may decrease

clinical phase of dementia to be considered, dietary intake data was

specificity, particularly if such drugs are used off-label in Denmark.

only captured at baseline and dietary habits may have changed over the

Dementia can only be definitively diagnosed post mortem, although

23 years of follow-up. Any such changes, however, would likely have

brain imaging increases diagnostic accuracy significantly. This raises

attenuated the observed association. Due to the number of flavonoid

the issue of individuals being incorrectly classified (particularly with

subclasses and their individual flavonoid compounds making up the

respect to dementia subtypes). The ICD-10 registration of subtypes of
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dementia is underreported in the DNPR and thus subtype analysis
should be interpreted with

caution.26

Finally, the participants in this

study were most likely White, meaning that caution should be taken
when extrapolating these findings to other ethnicities. Further studies
in other populations are required to confirm our findings.
In conclusion, in this large prospective cohort study of Danish men
and women we observed that a moderate and achievable dietary intake
of total flavonoids was associated with significantly lower risk of vascular dementia. Specific subclasses, flavanol oligo + polymers and
flavonols, were associated with a lower risk of both incident and vascular dementia. Our results suggest that small changes to the habitual diet, encouraging consumption of flavonoid-rich foods among lowflavonoid consumers may help to lower the risk of dementia.
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